Shilpa Medicare Limited — Important, 14-05-2025: General Updates

Shilpa Pharma Lifesciences, a fully-owned subsidiary of Shilpa Medicare, received a minor observation status (VAI) from the USFDA for Unit-1 after inspection. No major compliance issues were found, supporting smooth operations and export potential from the facility. This positive outcome reduces regulatory risk and helps maintain supply continuity.